Formula Swiss Medical ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
Estimate generation in progress, please wait...
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.1% 1.1% 1.1% 1.1% 1.1%  
Bankruptcy risk  0.0% 0.0% 9.6% 8.2% 6.3%  
Credit score (0-100)  0 0 24 29 31  
Credit rating  N/A N/A B B BB  
Credit limit (kDKK)  0.0 0.0 -0.0 -0.0 -0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 -69.2 -241 -21.9  
EBITDA  0.0 0.0 -69.2 -241 -21.9  
EBIT  0.0 0.0 -69.2 -241 -21.9  
Pre-tax profit (PTP)  0.0 0.0 -69.4 -241.2 -21.8  
Net earnings  0.0 0.0 -69.4 -241.2 -21.8  
Pre-tax profit without non-rec. items  0.0 0.0 -69.4 -241 -21.8  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 0.0 -29.4 -271 -292  
Interest-bearing liabilities  0.0 0.0 42.0 423 242  
Balance sheet total (assets)  0.0 0.0 38.7 161 138  

Net Debt  0.0 0.0 14.6 262 107  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 -69.2 -241 -21.9  
Gross profit growth  0.0% 0.0% 0.0% -247.7% 90.9%  
Employees  0 0 0 1 1  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 39 161 138  
Balance sheet change%  0.0% 0.0% 0.0% 317.5% -14.8%  
Added value  0.0 0.0 -69.2 -240.7 -21.9  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 -1.0 -2.0 -3.0  

Profitability 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% -101.7% -96.3% -5.1%  
ROI %  0.0% 0.0% -164.8% -103.5% -6.6%  
ROE %  0.0% 0.0% -179.5% -241.1% -14.6%  

Solidity 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% -43.2% -62.6% -68.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -21.1% -108.7% -489.2%  
Gearing %  0.0% 0.0% -142.9% -156.3% -82.8%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.8% 0.2% -0.0%  

Liquidity 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 0.6 0.4 0.3  
Current Ratio  0.0 0.0 0.6 0.4 0.3  
Cash and cash equivalent  0.0 0.0 27.4 161.4 135.1  

Capital use efficiency 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 -29.4 -270.6 -292.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 -241 -22  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 -241 -22  
EBIT / employee  0 0 0 -241 -22  
Net earnings / employee  0 0 0 -241 -22